Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 301–400 of 1,001
Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology
Sasaki, N., & Clevers, H. C. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.09.001 · Cited by 81
Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids
Sharick, J. T., Jeffery, J. J., Karim, M. R., Walsh, C. M., Esbona, K., Cook, R. S., & Skala, M. C. (2019) · Neoplasia · doi:10.1016/j.neo.2019.04.004 · Cited by 74
Bovine colon organoids: From 3D bioprinting to cryopreserved multi-well screening platforms
Töpfer, E., Pasotti, A., Telopoulou, A., Italiani, P., Boraschi, D., Ewart, M., & Wilde, C. J. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.104606 · Cited by 78
Drug screening model meets cancer organoid technology
Liu, C., Qin, T., Huang, Y., Li, Y., Chen, G., & Sun, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100840 · Cited by 71
The landscape of drug sensitivity and resistance in sarcoma
Shihabi, A. A., Tebon, P. J., Nguyen, H. T. L., Chantharasamee, J., Sartini, S., Davarifar, A., Jensen, A. Y., Diaz-Infante, M. B., Cox, H., Gonzalez, A. E., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.08.010 · Cited by 86
3D tumor cultures for drug resistance and screening development in clinical applications
Peng, Z., Lv, X., Sun, H., Zhao, L., & Huang, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02281-2 · Cited by 88
“Consequently, tumor organ-oids have limitations for clinical application, such as the inability to predict responses [63]to drugs like antiangio-genesis and immunotherapy.”
InfluentialFrom 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research
Rauner, G., Gupta, P. B., & Kuperwasser, C. (2025) · Nature Methods · doi:10.1038/s41592-025-02769-1 · Cited by 87
“The diversity of PDOs underscores their transformative potential in advancing personalized medicine, including the identification of patient-matched therapeutic vulnerabilities and the development of targeted treatment strategies 50,94–96 .”
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
Organoid Cultures Derived From Patients With Papillary Thyroid Cancer
Chen, D., Tan, Y., Li, Z., Li, W., Yu, L., Chen, W., Liu, Y., Liu, L., Guo, L., Huang, W., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab020 · Cited by 77
“A study comparing drug responses of patient-derived gastrointestinal cancer organoids with the responses of patients in clinical trials is very encouraging (15).”
BackgroundSundar, S. J., Shakya, S., Barnett, A., Wallace, L. C., Jeon, H.-M., Sloan, A. E., Recinos, V. R., & Hubert, C. G. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101251 · Cited by 78
Organoid technology in cancer precision medicine
Xia, X., Li, F., He, J., Aji, R., & Gao, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.039 · Cited by 76
Kawasaki, K., Rekhtman, N., Quintanal-Villalonga, À., & Rudin, C. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00696-0 · Cited by 77
Jensen, L. H., Rogatto, S. R., Lindebjerg, J., Havelund, B. M., Abildgaard, C., do Canto, L. M., Vagn-Hansen, C., Dam, C., Rafaelsen, S. R., & Hansen, T. F. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02683-4 · Cited by 77
“[22] established a biobank of TDOs, including those of 16 patients with heavily treated colorectal cancer.”
BackgroundTowards manufacturing of human organoids
Ashok, A., Choudhury, D., Fang, Y., & Hunziker, W. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107460 · Cited by 74
Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses
Ramos Zapatero, M., Tong, A., Opzoomer, J. W., O’Sullivan, R., Cardoso Rodriguez, F., Sufi, J., Vlckova, P., Nattress, C., Qin, X., Claus, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.005 · Cited by 72
Establishment of Pancreatic Organoids from Normal Tissue and Tumors
Driehuis, E., Gracanin, A., Vries, R. G. J., Clevers, H., & Boj, S. F. (2020) · STAR Protocols · doi:10.1016/j.xpro.2020.100192 · Cited by 71
“For example, a high percentage of pancreatic adenocarcinomas is known to harbor a mutation in KRAS (Waters and Der, 2018), resulting in ligand-independent signaling of the EGFR pathways.”
BackgroundEx vivo culture of intact human patient derived pancreatic tumour tissue
Kokkinos, J., Sharbeen, G., Haghighi, K. S., Ignacio, R. M. C., Kopecky, C., Gonzales‐Aloy, E., Youkhana, J., Timpson, P., Pereira, B., Ritchie, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81299-0 · Cited by 78
Jung, M., Ghamrawi, S., Du, E. Y., Gooding, J. J., & Kavallaris, M. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200690 · Cited by 81
Smabers, L. P., Wensink, G. E., Veríssimo, C. S., Koedoot, E., Pitsa, K.-C., Huismans, M. A., Barón, C. H., Doorn, M., Iersel, L. V., Cirkel, G. A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02980-6 · Cited by 91
Human Microphysiological Systems and Organoids as in Vitro Models for Toxicological Studies
Truskey, G. A. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00185 · Cited by 81
“Human iPS cells can be differentiated into specific tissues to study disease development (13), cancer (27), infections of brain and gut-microbiome organoids (28), and generate models of cystic fibrosis (29).”
BackgroundAdvances in colon cancer research: in vitro and animal models
Lannagan, T. R. M., Jackstadt, R., Leedham, S. J., & Sansom, O. J. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.003 · Cited by 79
“Strikingly, treatment response following orthotopic transplantation of liver metastasis or rectal tumour PDOs into immunedeficient mice correlated with patient response [23 ,24].”
MethodSelf-citationHigh-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., Frydenberg, M., Grummet, J., Sandhu, S., Hickey, T. E., et al. (2021) · SLAS Discovery · doi:10.1177/24725552211020668 · Cited by 69
Novel patient-derived preclinical models of liver cancer
Bresnahan, E., Ramadori, P., Heikenwalder, M., Zender, L., & Lujambio, A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.028 · Cited by 67
Acoustic Bioprinting of Patient‐Derived Organoids for Predicting Cancer Therapy Responses
Chen, H., Wu, Z., Gong, Z., Xia, Y., Li, J., Du, L., Zhang, Y., Gao, X., Zhou, F., Hu, H., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102784 · Cited by 74
Patient‐derived cancer organoids for drug screening: Basic technology and clinical application
Ren, X., Chen, W., Yang, Q., Li, X., & Xu, L. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15930 · Cited by 78
Harnessing Tumor Evolution to Circumvent Resistance
McNamara, K. L., & Curtis, C. N. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.007 · Cited by 78
“As such, these represent powerful platforms for drug screening [93], studying treatment response [94,95], and improving our understanding of the dynamics and mechanisms of resistance.”
BackgroundTargeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
Otto, C., Schmidt, S., Kastner, C., Denk, S., Kettler, J., Müller, N., Germer, C., Wolf, E., Gallant, P., & Wiegering, A. (2019) · Neoplasia · doi:10.1016/j.neo.2019.10.003 · Cited by 71
“Organoid isolation and culture were performed as described elsewhere [24].”
MethodAhmed, N., Kadife, E., Raza, A., Short, M. K., Jubinsky, P. T., & Kannourakis, G. (2020) · Cells · doi:10.3390/cells9030719 · Cited by 72
Organoids to study immune functions, immunological diseases and immunotherapy
Ye, W., Luo, C., Li, C., Huang, J., & Liu, F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.027 · Cited by 67
From engineered heart tissue to cardiac organoid
Cho, J., Lee, H., Rah, W., Chang, H., & Yoon, Y. (2022) · Theranostics · doi:10.7150/thno.67661 · Cited by 74
“Cells in 3D cultures exhibited less sensitivity to drugs [21] and mechanical stimuli [22], and resistance to apoptotic signaling [23], suggesting the need for 3D culture of hPSC-CMs for appropriate drug testing [24-27].”
BackgroundThe small intestine: dining table of host–microbiota meetings
Delbaere, K., Roegiers, I. H., Bron, A., Durif, C., de Wiele, T. V., Blanquet‐Diot, S., & Marinelli, L. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad022 · Cited by 79
Organotypic culture assays for murine and human primary and metastatic-site tumors
Padmanaban, V., Grasset, E. M., Neumann, N. M., Fraser, A. K., Henriet, E., Matsui, W. H., Tran, P. T., Cheung, K. J., Georgess, D., & Ewald, A. J. (2020) · Nature Protocols · doi:10.1038/s41596-020-0335-3 · Cited by 72
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
BackgroundShuford, S., Wilhelm, C., Rayner, M., Elrod, A., Millard, M., Mattingly, C., Lotstein, A., Smith, A. M., Guo, Q. J., O’Donnell, L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47578-7 · Cited by 66
One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids
Geurts, M. H., Gandhi, S., Boretto, M. G., Akkerman, N., Derks, L. L. M., van Son, G., Celotti, M., Harshuk-Shabso, S., Peci, F., Begthel, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40701-3 · Cited by 66
Predictive biomarkers for drug response in bladder cancer
Yoshida, T., Kates, M. R., Fujita, K., Bivalacqua, T. J., & McConkey, D. J. (2019) · International Journal of Urology · doi:10.1111/iju.14082 · Cited by 65
Neufert, C. F., Heichler, C., Brabletz, T., Koop, K., Boonsanay, V., Greten, F. R., & Neurath, M. F. (2020) · Nature Protocols · doi:10.1038/s41596-020-00412-1 · Cited by 71
Patient-Derived Organoids as a Model for Cancer Drug Discovery
Rae, C., Amato, F., & Braconi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073483 · Cited by 62
“Importantly, the characteristics of the tumours should also be maintained in the organoids at different passages, and this has been demonstrated in organoids derived from colorectal and gastric cancer [3,5,6].”
BackgroundSelf-citationOrganoids and Colorectal Cancer
Barbáchano, A., Fernández‐Barral, A., Bustamante‐Madrid, P., Prieto, I., Rodríguez-Salas, N., Larriba, M. J., & Múñoz, A. (2021) · Cancers · doi:10.3390/cancers13112657 · Cited by 81
“In a first study, the comparison of the therapy response of 23 colorectal and gastroesophageal cancer patients in clinical trials and that of their PDTOs showed an 88% positive predictive value and, importantly, a 100% negative predictive value [121].”
ResultBeutel, A. K., Schütte, L., Scheible, J., Roger, E., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., et al. (2021) · Cancers · doi:10.3390/cancers13112539 · Cited by 65
“PDO-derived gene signatures in PC were found to predict chemotherapy sensitivity [19], and in vitro drug responses correlated with clinical response in various patient examples in gastrointestinal cancers [20,21].”
Development of a human skeletal micro muscle platform with pacing capabilities
Mills, R. J., Parker, B. L., Monnot, P., Needham, E. J., Vivien, C. J., Ferguson, C., Parton, R. G., James, D. E., Porrello, E. R., & Hudson, J. E. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.030 · Cited by 69
Kim, S., Choung, S., Sun, R., Ung, N. M., Hashemi, N., Fong, E. J., Lau, R., Spiller, E. R., Gasho, J. O., Foo, J., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220915827 · Cited by 73
A path to translation: How 3D patient tumor avatars enable next generation precision oncology
Bose, S., Barroso, M., Chheda, M. G., Clevers, H. C., Élez, E., Kaochar, S., Kopetz, S., Li, X., Meric‐Bernstam, F., Meyer, C. A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.017 · Cited by 67
Ryoo, H., Kimmel, H., Rondo, E., & Underhill, G. H. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10627 · Cited by 75
“255 Kim et al. established 80 unique lung cancer organoids from different lung cancer samples, as well as five different normal bronchial organoids for the creation of a biobank.”
BackgroundOrganoid Models for Cancer Research
Clevers, H. C., & Tuveson, D. A. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055702 · Cited by 75
Taverna, J. A., Hung, C., DeArmond, D. T., Chen, M., Lin, C.-L., Osmulski, P. A., Gaczynska, M. E., Wang, C., Lucio, N. L. L., Chou, C., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3183 · Cited by 72
“Ex vivo drug testing of PDOs recapitulates tumor growth and can more accurately predict individual treatment responses to anti-AXL and -JAK combinations compared with other preclinical models (30).”
BackgroundHou, X., Du, C., Lu, L., Yuan, S., Zhan, M., You, P., & Du, H. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02510-8 · Cited by 77
“Superior to the PDX, tumors in all grades can be theoretically used to establish a PDO [51].”
BackgroundMethodTumor organoid biobank-new platform for medical research
Xie, X., Li, X., & Song, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-29065-2 · Cited by 80
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Codrich, M., Dalla, E., Mio, C., Antoniali, G., Malfatti, M. C., Marzinotto, S., Pierobon, M., Baldelli, E., Loreto, C. D., Damante, G., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01986-8 · Cited by 65
Calandrini, C., van Hooff, S. R., Paassen, I., Ayyildiz, D., Derakhshan, S., Dolman, M. E. M., Langenberg, K. P. S., van de Ven, M., de Heus, C., Liv, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109568 · Cited by 62
Laoukili, J., Constantinides, A., Wassenaar, E. C. E., Elias, S. G., Raats, D., van Schelven, S. J., van Wettum, J., Volckmann, R., Köster, J., Huitema, A. D. R., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01742-5 · Cited by 70
Hogenson, T. L., Xie, H., Phillips, W. J., Toruner, M. D., Li, J., Horn, I. P., Kennedy, D. J., Almada, L. L., Marks, D. L., Carr, R. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158060 · Cited by 75
“In 1 case, the CCA donor patient was treated in a clinical trial with TAS-102 and showed PD, while the corresponding PDO (HO42) was sensitive.”
InfluentialBioengineering Organs for Blood Detoxification
Legallais, C., Kim, D., Mihaila, S. M., Mihajlovic, M., Figliuzzi, M., Bonandrini, B., Salerno, S., Yengej, F. A. Y., Rookmaaker, M. B., Romero, N. S., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800430 · Cited by 71
A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture
Chakrabarty, S., Quiros-Solano, W. F., Kuijten, M. M. P., Haspels, B., Mallya, S., Lo, C. S. Y., Othman, A., Silvestri, C., van de Stolpe, A., Gaio, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-0799 · Cited by 61
“Defining features of this 405 microfluidic system are: (1) relatively large (tumor) tissue slices can be loaded, (2) flow of culture media 406 both above and under the tissue slice to sustain constant delivery of nutrients and gasses and removal of 407 waste products, (3) mainly silicon-based components, (4) standard…”
BackgroundOrganoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 66
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 67
Prasad, M., Kumar, R., Buragohain, L., Kumari, A., & Ghosh, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696668 · Cited by 63
Chen, L., Wei, X., Gu, D., Xu, Y., & Zhou, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216048 · Cited by 61
Breaking the mold: 3D cell cultures reshaping the future of cancer research
Cordeiro, S. Z., Oliveira, B. B. P. P., Valente, R., Ferreira, D., Luz, A., Baptista, P. V., & Fernandes, A. R. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1507388 · Cited by 76
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 64
The frontier of live tissue imaging across space and time
Huang, Q., Garrett, A., Bose, S., Blocker, S. J., Rios, A. C., Clevers, H. C., & Shen, X. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.02.010 · Cited by 63
“, 2020), and esophageal (Drost et al., 2015; Vlachogiannis et al., 2018) cancer organoids.”
BackgroundPrecision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed
Pfohl, U., Pflaume, A., Regenbrecht, M., Finkler, S., Adelmann, Q. G., Reinhard, C., Regenbrecht, C. R. A., & Wedeken, L. (2021) · Cells · doi:10.3390/cells10040928 · Cited by 68
Wang, P., Zhou, R., Thomas, P. B., Zhao, L., Zhou, R., Mandal, S., Jolly, M. K., Richard, D. J., Rehm, B. H. A., Ostrikov, K., et al. (2021) · Cancers · doi:10.3390/cancers13122889 · Cited by 65
“Indeed, 3D models have emerged as a more highly representative culture format in cancer studies, particularly in relation to patientderived tumoroids, which have the potential to recapitulate the patient response to specific agents [53,54].”
BackgroundZhao, N., Powell, R. T., Yuan, X., Bae, G., Roarty, K. P., Stossi, F., Strempfl, M., Toneff, M. J., Johnson, H. L., Mani, S. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24545-3 · Cited by 77
Patient-Derived Organoids of Cholangiocarcinoma
Maier, C., Zhu, L., Nanduri, L. K., Kühn, D., Kochall, S., Thepkaysone, M.-L., William, D., Grützmann, K., Klink, B., Betge, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168675 · Cited by 60
“Patient-derived organoid xenografts (PDOXs) show drug responses comparable to the corresponding patient tumors, thus highlighting their value as an alternative in vivo model [62].”
BackgroundFarshadi, E. A., Chang, J., Sampadi, B., Doukas, M., Van 't Land, F., van der Sijde, F., Vietsch, E. E., Pothof, J., Koerkamp, B. G., & van Eijck, C. H. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1681 · Cited by 60
“These patient-derived organoids demonstrated great potential as a research model to predict therapy response in pancreatic cancer and other gastrointestinal cancers (19, 20).”
BackgroundImaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response
Spiller, E. R., Ung, N. M., Kim, S., Patsch, K., Lau, R., Strelez, C., Doshi, C., Choung, S., Choi, B., Juarez, E. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771173 · Cited by 67
“…organoids (PDOs), in which cells obtained from a patient ’ s tumor are grown in a medium that promotes the formation of cellular aggregates that recapitulate important aspects of the original tissue architecture, have gained signi fi cant traction in the cancer research fi eld (7 – 9).”
BackgroundThe role of organoids in cancer research
Fang, Z., Li, P., Du, F., Shang, L., & Li, L. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00433-y · Cited by 73
Tumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 64
Nayak, B., Balachander, G. M., Manjunath, S., Rangarajan, A., & Chatterjee, K. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.04.056 · Cited by 65
Engel, R. M., Chan, W. H., Nickless, D. K., Hlavca, S., Richards, E., Kerr, G., Oliva, K., McMurrick, P. J., Jardé, T., & Abud, H. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010128 · Cited by 64
Patient-derived organoids of non-small cells lung cancer and their application for drug screening
Li, Y. F., Gao, Y., Liang, B. W., Cao, X. Q., Sun, Z. J., Yu, J. H., Liu, Z. D., & Han, Y. (2020) · Neoplasma · doi:10.4149/neo_2020_190417n346 · Cited by 60
A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing
Saltsman, J. A., Hammond, W. J., Narayan, N. J. C., Requena, D., Gehart, H., Lalazar, G., LaQuaglia, M. P., Clevers, H., & Simon, S. (2020) · Cancers · doi:10.3390/cancers12092668 · Cited by 59
“Cancer organoids have now been shown to faithfully recapitulate key elements of disease including sequential mutation [33], treatment response [14,15], and host immune response to the tumor [34].”
BackgroundMethodOksdath, M., Perrin, S. L., Bardy, C., Hilder, E. F., DeForest, C. A., Arrua, R. D., & Gomez, G. A. (2018) · APL Bioengineering · doi:10.1063/1.5045124 · Cited by 68
“Brain organoids have also attracted significant interest in clinical settings, with high applicability for personalized medicine, since in other contexts, organoids have been shown to re-produce personalized clinical outcomes (Vlachogiannis et al., 2018).”
BackgroundDiscovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 64
Forsythe, S. D., Sasikumar, S., Moaven, O., Sivakumar, H., Shen, P., Levine, E. A., Söker, S., Skardal, A., & Votanopoulos, K. I. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08790-2 · Cited by 61
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
Marín, J. J. G., Prete, M. G., Lamarca, Á., Tavolari, S., Landa-Magdalena, A., Brandi, G., Segatto, O., Vogel, A., Macías, R. I. R., Rodrigues, P. M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0987-3 · Cited by 62
Self-citationWang, T., Pan, W., Zheng, H., Zheng, H., Wang, Z., Li, J. J., Deng, C., & Yan, J. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001971 · Cited by 66
“RESULTADOS: La mediana (rango) de tiempo de cultivo organoide y prueba de drogas fue de 9 (7-14) días.”
BackgroundCastro, F., Pereira, C. L., Macedo, M. H., Almeida, A., Silveira, M. J., Dias, S., Cardoso, A. P., Oliveira, M. J., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.06.001 · Cited by 66
Exploiting epigenetic dependencies in ovarian cancer therapy
Coughlan, A. Y., & Testa, G. (2021) · International Journal of Cancer · doi:10.1002/ijc.33727 · Cited by 61
Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
Bian, Y., Alem, D., Beato, F., Hogenson, T. L., Yang, X., Jiang, K., Cai, J., Ma, W. W., Fernández-Zapico, M. E., Tan, A. C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01300 · Cited by 64
Organoids in high-throughput and high-content screenings
Lampart, F. L., Iber, D., & Doumpas, N. (2023) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2023.1120348 · Cited by 66
“The group generated patientderived organoid models of metastatic gastrointestinal cancer and used them to predict patient treatment responses (Vlachogiannis et al., 2018).”
MethodA comprehensive review of 3D cancer models for drug screening and translational research
Sharma, K., Dey, S., Karmakar, R., & Rengan, A. K. (2023) · Cancer Innovation · doi:10.1002/cai2.102 · Cited by 62
“Similarly, there are studies validating that Patient Derived Organoids (PDOs) can recapitulate norms of patient response while being used for pharmacotherapy and may contribute to dedicated research in personalized medicine [67].”
BackgroundMultiplexed single-cell analysis of organoid signaling networks
Sufi, J., Qin, X., Rodriguez, F. C., Bu, Y. J., Vlckova, P., Zapatero, M. R., Nitz, M., & Tape, C. J. (2021) · Nature Protocols · doi:10.1038/s41596-021-00603-4 · Cited by 57
3D Cancer Models: Depicting Cellular Crosstalk within the Tumour Microenvironment
Franchi-Mendes, T., Eduardo, R., Domenici, G., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13184610 · Cited by 67
The future of tumor organoids in precision therapy
Kim, S., van de Wetering, M., Clevers, H. C., & Sanders, K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.03.005 · Cited by 69
Wang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
“36 The results revealed a high confidence of using PDOs in predicting responses to targeted therapies and chemotherapies in patients with 100% sensitivity and 93% specificity.”
BackgroundInfluentialPrecision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Assay establishment and validation of a high-throughput organoid-based drug screening platform
Li, X., Fu, G., Zhang, L., Guan, R., Tang, P., Zhang, J., Rao, X., Chen, S., Xu, X., Zhou, Y., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02902-3 · Cited by 64
Cancer organoids: A platform in basic and translational research
Ma, X., Wang, Q. L., Li, G., Li, H., Xu, S., & Pang, D. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.052 · Cited by 67
“It accurately reproduced the patient treatment response of gastrointestinal cancer with high sensitivity (100%), specificity (93%), positive predictive value (88%), and negative predictive value (100%).(131) Li et al used signet ring cell carcinoma (SRCC) and non-SRCC organoids to observe treatment responses to 5-fluo…”
BackgroundMayoh, C., Mao, J., Xie, J., Tax, G., Chow, S., Cadiz, R., Pazaky, K., Barahona, P., Ajuyah, P., Trebilcock, P., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3702 · Cited by 59
Cancer chemoprevention: signaling pathways and strategic approaches
Ren, J., Yan, G., Yang, L., Kong, L., Guan, Y., Sun, H., Liu, C., Liu, L., Han, Y., & Wang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02167-1 · Cited by 84
Clinton, J., & McWilliams‐Koeppen, P. (2019) · Current Protocols in Cell Biology · doi:10.1002/cpcb.66 · Cited by 56
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy
Taurin, S., Alzahrani, R., Aloraibi, S., Ashi, L., AlHarmi, R. A. R., & Hassani, N. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102226 · Cited by 59
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Gao, M., Lin, M., Moffitt, R. A., Salazar, M. D., Park, J. M., Vacirca, J. L., Huang, C., Shroyer, K. R., Choi, M., Georgakis, G. V., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0298-0 · Cited by 55
Lu, I., Dobersalske, C., Rauschenbach, L., Teuber‐Hanselmann, S., Steinbach, A., Ullrich, V., Prasad, S., Blau, T., Kebir, S., Siveke, J. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23995-z · Cited by 56
Granat, L. M., Kambhampati, O., Klosek, S., Niedzwecki, B., Parsa, K., & Zhang, D. (2019) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12077 · Cited by 62
Langenberg, K. P. S., Looze, E. J., & Molenaar, J. J. (2021) · Cancers · doi:10.3390/cancers13174324 · Cited by 63
Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation
Zhou, J., Tang, D., He, L., Lin, S., Lei, J. H., Sun, H., Xu, X., & Deng, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106830 · Cited by 57
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.